Your browser doesn't support javascript.
loading
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Burgos, Leire; Tamariz-Amador, Luis-Esteban; Puig, Noemi; Cedena, Maria-Teresa; Guerrero, Camila; Jelínek, Tomas; Johnson, Sarah; Milani, Paolo; Cordon, Lourdes; Perez, Jose J; Lasa, Marta; Termini, Rosalinda; Oriol, Albert; Hernandez, Miguel-Teodoro; Palomera, Luis; Martinez-Martinez, Rafael; de la Rubia, Javier; de Arriba, Felipe; Rios, Rafael; Gonzalez, Maria-Esther; Gironella, Mercedes; Cabañas, Valentin; Casanova, Maria; Krsnik, Isabel; Perez-Montaña, Albert; González-Calle, Verónica; Rodriguez-Otero, Paula; Maisnar, Vladimir; Hajek, Roman; Van Rhee, Fritz; Jimenez-Zepeda, Victor; Palladini, Giovanni; Merlini, Giampaolo; Orfao, Alberto; de la Cruz, Javier; Martinez-Lopez, Joaquin; Lahuerta, Juan-Jose; Rosiñol, Laura; Blade, Joan; Mateos, Maria-Victoria; San-Miguel, Jesus F; Paiva, Bruno.
Afiliação
  • Burgos L; Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain.
  • Tamariz-Amador LE; Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain.
  • Puig N; Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain.
  • Cedena MT; Hematology Department, Hospital Universitario 12 de Octubre, CIBERONC, Instituto de Investigación IMAS12, Madrid, Spain.
  • Guerrero C; Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain.
  • Jelínek T; Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
  • Johnson S; Myeloma Center/Division of Hematology Oncology/Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
  • Milani P; Department of Molecular Medicine, University of Pavia and Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Cordon L; Hospital Universitario La Fe, Valencia, Spain.
  • Perez JJ; Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain.
  • Lasa M; Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain.
  • Termini R; Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain.
  • Oriol A; Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
  • Hernandez MT; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
  • Palomera L; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
  • Martinez-Martinez R; Hospital Clínico San Carlos, Madrid, Spain.
  • de la Rubia J; Hematology Department, University Hospital La Fe, Valencia, Spain.
  • de Arriba F; Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.
  • Rios R; Hospital Universitario Puerta de Hierro, Hospital, Madrid, Spain.
  • Gonzalez ME; Hospital de Cabueñes, Gijón, Spain.
  • Gironella M; Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.
  • Cabañas V; Hospital Clínico Universitario Virgen de la Arrixaca. IMIB-Arrixaca. University of Murcia, Murcia, Spain.
  • Casanova M; Hematology Department, Hospital Costa del Sol Marbella, Marbella, Spain.
  • Krsnik I; Hospital Universitario Puerta de Hierro, Hospital, Madrid, Spain.
  • Perez-Montaña A; Hospital Universitario Son Espases, Palma, Spain.
  • González-Calle V; Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain.
  • Rodriguez-Otero P; Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain.
  • Maisnar V; 4th Department of Medicine-Haematology, Charles University Hospital, Hradec Králové, Czech Republic.
  • Hajek R; Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
  • Van Rhee F; Myeloma Center/Division of Hematology Oncology/Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
  • Jimenez-Zepeda V; Tom Baker Cancer Center, Department of Hematology, University of Calgary, Calgary, AB, Canada.
  • Palladini G; Department of Molecular Medicine, University of Pavia and Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Merlini G; Department of Molecular Medicine, University of Pavia and Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Orfao A; Hospital Universitario de Salamanca (HUSAL), IBSAL, Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, University of Salamanca, CIBERONC, Salamanca, Spain.
  • de la Cruz J; Hematology Department, Hospital Universitario 12 de Octubre, CIBERONC, Instituto de Investigación IMAS12, Madrid, Spain.
  • Martinez-Lopez J; Hematology Department, Hospital Universitario 12 de Octubre, CIBERONC, Instituto de Investigación IMAS12, Madrid, Spain.
  • Lahuerta JJ; Hematology Department, Hospital Universitario 12 de Octubre, CIBERONC, Instituto de Investigación IMAS12, Madrid, Spain.
  • Rosiñol L; Amyloidosis and Myeloma Unit. Department of Hematology. Hospital Clínic de Barcelona. IDIBAPS., Barcelona, Spain.
  • Blade J; Amyloidosis and Myeloma Unit. Department of Hematology. Hospital Clínic de Barcelona. IDIBAPS., Barcelona, Spain.
  • Mateos MV; Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain.
  • San-Miguel JF; Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain.
  • Paiva B; Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain.
J Clin Oncol ; 41(16): 3019-3031, 2023 06 01.
Article em En | MEDLINE | ID: mdl-36930848
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paraproteinemias / Gamopatia Monoclonal de Significância Indeterminada / Amiloidose de Cadeia Leve de Imunoglobulina / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paraproteinemias / Gamopatia Monoclonal de Significância Indeterminada / Amiloidose de Cadeia Leve de Imunoglobulina / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article